Inventor
Bernard Bourrie
Inventor
Saint Gely du Fesc, FR
Overview
Patents· 30 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations35%
A61KPreparations for medical, dental or toiletry purposes25%
C07DHeterocyclic compounds23%
Y10STechnical subjects covered by former uspc cross-reference art collections [xracs] and digests6%
C07KPeptides5%
A43BCharacteristic features of footwear1%
B29CShaping or joining of plastics1%
B29DProducing particular articles from plastics or from substances in a plastic state1%
C07CAcyclic or carbocyclic compounds1%
Y02ATechnologies for adaptation to climate change1%
PatentTitleYear
8,236,811'Therapeutic use for treating of leukemia'20128,063,061'6-heteroarylpyridoindolone derivatives, their preparation and therapeutic use thereof'20118,012,991'Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics'20118,008,310'Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same'20117,893,259'Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof'20117,858,824'Aralkyltetrahydropyridines, their preparation and pharmaceutical compositions containing them'20107,842,806'Pyridopyrimidone derivatives, preparation thereof, therapeutic use thereof'20107,816,368'Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics'20107,812,165'6-substituted pyridoindolone derivatives, production and therapeutic use thereof'20107,544,682'Pyrido-pyrimidine derivatives, preparation thereof, and therapeutic use thereof'20097,524,857'Pharmaceutical combinations based on pyridoindolone derivatives and anticancer agents'20097,504,406'Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same'20097,456,193'Pyridoindolone derivatives substituted in the 3-position by a heterocyclic group, their preparation and their application in therapeutics'20087,390,818'Pyridoindolone derivatives substituted in the 3-position by a phenyl, their preparation and their application in therapeutics'20087,326,723'Aralkyl-tetrahydro-pyridines, their preparation and pharmaceutical compositions containing same'20087,326,720'Phenyl- and pyridylpiperidines with TNF activity'20087,211,578'Nitrogenous tetrahydropyridyl-alkyl-heterocycles with TNF activity'20077,186,720'Tetrahydropyridyl-alkyl-heterocycles, method for preparing the same and pharmaceutical compositions containing the same'20077,160,895'Use of pyridoindolone derivatives for the preparation of medicinal products'20076,967,203'Use of pyridoindolone derivatives for preparing anticancer medicines'20056,689,797'Tetrahydropyridines, preparation method and pharmaceutical compositions containing same'20046,642,258'Use of central cannabinoid receptor antagonist for preparing medicines'20036,509,351'Phenyl- and pyridyl-tetrahydro-pyridines having TNF inhibiting activity'20036,482,986'Benzene derivatives, preparation method and pharmaceutical compositions containing same'20026,344,464'Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination'20025,106,956'Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and reduction, and in vivo prolonged-action immunotoxins containing such a glycoprotein'19925,104,976'Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a Schiff\'s base and in-vivo prolonged action immunotoxins containing such a glycoprotein'19924,911,912'Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and reduction, and in vivo prolonged-action immunotoxins containing such a glycoprotein'19904,911,911'Ribosome-inactivating glycoproteins, modified by oxidation of their osidic units and formation of a schiff\'s base and in-vivo prolonged action immunotoxins containing such a glycoprotein'19904,749,566'Pharmaceutical composition comprising a combination of at least one immunotoxin and at least one mannose-containing polymer'1988Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
1988–2012Patents assigned to SANOFI SA (6)· patent assignee history
1988–1992Based in Montpellier, FR· patent location history
2002–2004Patents assigned to SANOFI SYNTHELABO (4)· patent assignee history
2002–2011Based in Saint Gely du Fesc, FR· patent location history
2005–2011Patents assigned to SANOFI AVENTIS (19)· patent assignee history
2011–2012Patents assigned to BOURRIE BERNARD (2)· patent assignee history
2011–2012Patents assigned to CASELLAS PIERRE (2)· patent assignee history
2012Based in Paris, FR· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| SANOFI AVENTIS | 19 | 2005–2011 |
| SANOFI SA | 6 | 1988–2012 |
| SANOFI SYNTHELABO | 4 | 2002–2004 |
| BOURRIE BERNARDself | 2 | 2011–2012 |
| CASELLAS PIERRE | 2 | 2011–2012 |
Locations
| Location | Patents | Span |
|---|---|---|
| Saint Gely du Fesc, FR | 24 | 2002–2011 |
| Montpellier, FR | 5 | 1988–1992 |
| Paris, FR | 1 | 2012 |